Form 4: Acurx Pharmaceuticals CEO David P. Luci Granted Stock Options

Acurx Pharmaceuticals' CEO, David P. Luci, was granted stock options to purchase 250,000 shares of the company's common stock on February 5, 2025.

Summary

• David P. Luci, the President and CEO of Acurx Pharmaceuticals, Inc., was granted stock options on February 5, 2025.
• The stock options allow him to purchase 250,000 shares of Acurx's common stock at an exercise price of $0.7982 per share.
• The options vest immediately and expire on February 5, 2035.
• This transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a standard executive compensation practice. It's neither particularly positive nor negative from an investment perspective.

Positives

• The immediate vesting of the options could incentivize the CEO to drive short-term performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• The size and vesting schedule of the grant would need to be compared to similar companies to determine if it is in line with industry standards.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could incentivize the CEO to increase shareholder value.

Key Dates

Keywords

stock options, Acurx Pharmaceuticals, David P. Luci, CEO, Form 4, beneficial ownership, ACXP